ATE199568T1 - Cytopatische viren zur therapie und prophylaxe der neoplasie - Google Patents
Cytopatische viren zur therapie und prophylaxe der neoplasieInfo
- Publication number
- ATE199568T1 ATE199568T1 AT98121753T AT98121753T ATE199568T1 AT E199568 T1 ATE199568 T1 AT E199568T1 AT 98121753 T AT98121753 T AT 98121753T AT 98121753 T AT98121753 T AT 98121753T AT E199568 T1 ATE199568 T1 AT E199568T1
- Authority
- AT
- Austria
- Prior art keywords
- replication phenotype
- cells
- neoplastic cells
- viral
- neoplastic
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000009826 neoplastic cell growth Effects 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 4
- 230000010076 replication Effects 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 108010067390 Viral Proteins Proteins 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1752593A | 1993-02-16 | 1993-02-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE199568T1 true ATE199568T1 (de) | 2001-03-15 |
Family
ID=21783090
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98121753T ATE199568T1 (de) | 1993-02-16 | 1994-02-16 | Cytopatische viren zur therapie und prophylaxe der neoplasie |
| AT94910177T ATE178490T1 (de) | 1993-02-16 | 1994-02-16 | Cytopathische viren zur therapie und prophylaxe der neoplasie |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94910177T ATE178490T1 (de) | 1993-02-16 | 1994-02-16 | Cytopathische viren zur therapie und prophylaxe der neoplasie |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP0689447B1 (de) |
| JP (2) | JP3556666B2 (de) |
| AT (2) | ATE199568T1 (de) |
| AU (1) | AU682854B2 (de) |
| CA (1) | CA2152941C (de) |
| DE (2) | DE69417734T2 (de) |
| DK (2) | DK0931830T3 (de) |
| ES (2) | ES2134346T3 (de) |
| GR (2) | GR3030385T3 (de) |
| PT (1) | PT931830E (de) |
| WO (1) | WO1994018992A1 (de) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| WO1992015680A1 (en) | 1991-03-06 | 1992-09-17 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| US5516631A (en) * | 1992-10-13 | 1996-05-14 | La Jolla Cancer Research Foundation | Method of inhibiting replication of hyperproliferative cells |
| EP2009119A1 (de) | 1993-04-30 | 2008-12-31 | Wellstat Biologics Corporation | Zusammensetzungen zur Behandlung von Krebs mittels Viren |
| US5776743A (en) | 1994-09-06 | 1998-07-07 | La Jolla Cancer Research Foundation | Method of sensitizing tumor cells with adenovirus E1A |
| ES2258265T3 (es) * | 1994-11-28 | 2006-08-16 | Cell Genesys Inc. | Vectores de replicacion con especificidad tisular. |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6326356B1 (en) | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
| US20030026789A1 (en) * | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
| US6004942A (en) * | 1995-08-30 | 1999-12-21 | The Regents Of The University Of California | Methods for treating arthritis by administering an apoptosis regulator |
| US6133243A (en) * | 1996-02-22 | 2000-10-17 | Onyx Pharmaceuticals, Inc. | Liposomal-viral DNA complexes for treating disease |
| US6054467A (en) * | 1996-07-05 | 2000-04-25 | Sidney Kimmel Cancer Center | Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis |
| US5958892A (en) | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
| AU4592697A (en) * | 1996-09-24 | 1998-04-17 | Dana-Farber Cancer Institute | Method of targeting malignant cells using an e2f responsive promoter |
| AU742696B2 (en) * | 1996-11-18 | 2002-01-10 | Mcgill University | Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth |
| US6080578A (en) * | 1996-12-31 | 2000-06-27 | Onyx Pharmaceuticals, Inc. | Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia |
| US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
| US6565831B1 (en) | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| US6136307A (en) | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6696423B1 (en) | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| US7780962B2 (en) | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
| US7470426B1 (en) | 1997-10-09 | 2008-12-30 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6020135A (en) * | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| EP1121442A2 (de) * | 1998-10-15 | 2001-08-08 | CANJI, Inc. | Rekombinante adenovirale vektoren die deletionen in der e1a-region enthalten |
| US7691370B2 (en) | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
| HU226602B1 (en) * | 1998-10-15 | 2009-04-28 | Canji | Selectively replicating viral vectors, pharmaceutical preparations containing them and process for producing them |
| US20020037274A1 (en) * | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| WO2000029573A2 (en) * | 1998-11-18 | 2000-05-25 | Canji, Inc. | Adenoviral vectors |
| GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
| JP2003530301A (ja) | 1999-04-15 | 2003-10-14 | ウェルスタット バイオロジクス コーポレイション | ウイルスを用いた新生物の処置 |
| DE19929569A1 (de) * | 1999-06-21 | 2000-12-28 | Holm Per Sonne | Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1 |
| US8147822B1 (en) | 1999-09-17 | 2012-04-03 | Wellstat Biologics Corporation | Oncolytic virus |
| ES2288488T3 (es) | 1999-11-15 | 2008-01-16 | Onyx Pharmaceuticals, Inc. | Adenovirus oncoliticos. |
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| US8491884B2 (en) | 2000-05-03 | 2013-07-23 | Oncolytics Biotech Inc. | Virus clearance of neoplastic cells from mixed cellular compositions |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| AR028039A1 (es) | 2000-05-03 | 2003-04-23 | Oncolytics Biotech Inc | Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas |
| AR035227A1 (es) | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
| WO2002068627A2 (en) | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constucts |
| CA2374388C (en) | 2002-02-28 | 2005-07-12 | Matthew C. Coffey | The use of ribozymes in the detection of adventitious agents |
| US20040005546A1 (en) | 2002-02-28 | 2004-01-08 | Oncolytics Biotech Inc. | Use of ribozymes in the detection of adventitious agents |
| EP1944035A1 (de) | 2002-05-09 | 2008-07-16 | Oncolytics Biotech Inc. | Verfahren zur Schmerzlinderung durch onkolytische Viren |
| CA2487811A1 (en) * | 2002-05-27 | 2003-12-04 | Per Sonne Holm | Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors |
| AU2011221393A1 (en) * | 2002-05-27 | 2011-09-29 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| RU2351361C2 (ru) * | 2002-05-27 | 2009-04-10 | Пер Сонне ХОЛЬМ | Новое применение аденовируса и кодирующих его нуклеиновых кислот |
| RU2393221C2 (ru) * | 2002-10-15 | 2010-06-27 | Пер Сонне ХОЛЬМ | Аденовирус с обращенной генной экспрессией и его применение |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| WO2005007857A1 (en) | 2003-07-21 | 2005-01-27 | Transgene S.A. | Polypeptide having an improved cytosine deaminase activity |
| EP1689445B1 (de) * | 2003-11-14 | 2015-02-25 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierende nukleinsäuren |
| KR100756055B1 (ko) | 2006-01-27 | 2007-09-07 | 연세대학교 산학협력단 | 신생혈관 생성을 조절하는 재조합 아데노바이러스 |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| JP2012515146A (ja) | 2009-01-13 | 2012-07-05 | トランジェーヌ、ソシエテ、アノニム | 免疫刺激のためのサッカロマイセス・セレビシエのミトコンドリア核酸画分の使用 |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| WO2012022496A2 (en) | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| KR20250081944A (ko) | 2014-09-24 | 2025-06-05 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP4155411A1 (de) | 2016-02-23 | 2023-03-29 | Salk Institute for Biological Studies | Exogene genexpression eines therapeutischen adenovirus mit geringem einfluss auf die virale kinetik |
| EP3532082A4 (de) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | Auf tumoren gerichtete synthetische adenoviren und verwendungen davon |
| US11896634B2 (en) | 2017-04-21 | 2024-02-13 | Baylor College Of Medicine | Oncolytic virotherapy with helper-dependent adenoviral-based vectors expressing immunomodulatory molecules |
| MX2020010499A (es) | 2018-04-09 | 2020-10-28 | Salk Inst For Biological Studi | Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2051289C (en) * | 1990-09-14 | 2002-11-26 | Robert L. Martuza | Viral mediated destruction of neoplastic cells |
-
1994
- 1994-02-16 AT AT98121753T patent/ATE199568T1/de active
- 1994-02-16 ES ES94910177T patent/ES2134346T3/es not_active Expired - Lifetime
- 1994-02-16 EP EP94910177A patent/EP0689447B1/de not_active Expired - Lifetime
- 1994-02-16 DK DK98121753T patent/DK0931830T3/da active
- 1994-02-16 EP EP98121753A patent/EP0931830B1/de not_active Expired - Lifetime
- 1994-02-16 JP JP51929494A patent/JP3556666B2/ja not_active Expired - Lifetime
- 1994-02-16 WO PCT/US1994/002049 patent/WO1994018992A1/en not_active Ceased
- 1994-02-16 AT AT94910177T patent/ATE178490T1/de active
- 1994-02-16 DE DE69417734T patent/DE69417734T2/de not_active Expired - Lifetime
- 1994-02-16 DK DK94910177T patent/DK0689447T3/da active
- 1994-02-16 DE DE69426841T patent/DE69426841T2/de not_active Expired - Lifetime
- 1994-02-16 CA CA002152941A patent/CA2152941C/en not_active Expired - Lifetime
- 1994-02-16 ES ES98121753T patent/ES2157109T3/es not_active Expired - Lifetime
- 1994-02-16 AU AU62722/94A patent/AU682854B2/en not_active Expired
- 1994-02-16 PT PT98121753T patent/PT931830E/pt unknown
-
1999
- 1999-06-01 GR GR990401479T patent/GR3030385T3/el unknown
-
2001
- 2001-05-22 GR GR20010400768T patent/GR3035914T3/el unknown
-
2003
- 2003-12-25 JP JP2003431544A patent/JP2004115543A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0931830B1 (de) | 2001-03-07 |
| DE69426841D1 (de) | 2001-04-12 |
| PT931830E (pt) | 2001-08-30 |
| DE69417734T2 (de) | 1999-10-07 |
| JPH08507076A (ja) | 1996-07-30 |
| JP3556666B2 (ja) | 2004-08-18 |
| EP0689447A1 (de) | 1996-01-03 |
| CA2152941C (en) | 2003-04-22 |
| EP0931830A2 (de) | 1999-07-28 |
| DE69417734D1 (de) | 1999-05-12 |
| EP0689447A4 (de) | 1997-06-04 |
| GR3030385T3 (en) | 1999-09-30 |
| DK0931830T3 (da) | 2001-06-11 |
| ATE178490T1 (de) | 1999-04-15 |
| DK0689447T3 (da) | 1999-10-18 |
| GR3035914T3 (en) | 2001-08-31 |
| WO1994018992A1 (en) | 1994-09-01 |
| AU6272294A (en) | 1994-09-14 |
| JP2004115543A (ja) | 2004-04-15 |
| AU682854B2 (en) | 1997-10-23 |
| EP0931830A3 (de) | 2000-07-12 |
| CA2152941A1 (en) | 1994-09-01 |
| ES2157109T3 (es) | 2001-08-01 |
| EP0689447B1 (de) | 1999-04-07 |
| ES2134346T3 (es) | 1999-10-01 |
| DE69426841T2 (de) | 2001-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69426841D1 (de) | Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie | |
| ATE256195T1 (de) | Cytopatische viren zur therapie und prophylaxe der neoplasie | |
| ES8307500A1 (es) | "metodo para inactivar los virus infecciosos contenidos en una composicion enzimatica hemocoagulante". | |
| FI862011A0 (fi) | Terapeutiska nukleosider. | |
| CA2051289A1 (en) | Viral mediated destruction of neoplastic cells | |
| DE3850154D1 (de) | Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression. | |
| NO943288L (no) | Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer | |
| DE69730153D1 (de) | EHV-1 Vektoren | |
| AU2833789A (en) | Non-reverting rna viruses | |
| ATE89569T1 (de) | Haemoglobin mit reduziertem virusrisiko und dessen herstellung. | |
| DK0480391T3 (da) | Emulgatorfrie emulsionspolymerer, deres fremstilling og deres anvendelse i farmaceutiske præparater med forlænget frigivelse af virksomt stof | |
| ATE255417T1 (de) | Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen | |
| ATE137968T1 (de) | Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen | |
| AU630099B2 (en) | Non-reverting rna viruses | |
| DE69422980D1 (de) | Extrakte von Piliostigma thonningii, deren Verwendung und diese enthaltende Zubereitungen | |
| AU630249B2 (en) | Prevention of glycoprotein enveloped virus infectivity by quinolyloxazole-2-ones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |